Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

81. Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial

Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial We evaluated the effect of Internet-based cognitive behavioral therapy (iCBT), with or without therapist support, on the perceived impact of hot flushes and night sweats (HF/NS) and overall levels of menopausal symptoms (primary outcomes), sleep quality, HF/NS frequency, sexual functioning, psychological distress, and health (...) -related quality of life in breast cancer survivors with treatment-induced menopausal symptoms.We randomly assigned 254 breast cancer survivors to a therapist-guided or a self-managed iCBT group or to a waiting list control group. The 6-week iCBT program included psycho-education, behavior monitoring, and cognitive restructuring. Questionnaires were administered at baseline and at 10 weeks and 24 weeks postrandomization. We used mixed-effects models to compare the intervention groups with the control

2019 EvidenceUpdates

82. Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix

Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/886373/2018 EMEA/H/C/004697 Zirabev (bevacizumab) An overview of Zirabev and why (...) it is authorised in the EU What is Zirabev and what is it used for? Zirabev is a cancer medicine that is used to treat adults with the following cancers: • cancer of the colon (large bowel) or the rectum (the last section of the bowel), when it has spread to other parts of the body; • breast cancer that has spread to other parts of the body; • a lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Zirabev can be used unless the cancer

2019 European Medicines Agency - EPARs

83. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer P Pertuzumab for adjuvant treatment of ertuzumab for adjuvant treatment of HER2-positiv HER2-positive early stage breast cancer e early stage breast cancer T echnology appraisal guidance Published: 20 March 2019 nice.org.uk/guidance/ta569 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

84. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. (PubMed)

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy. We now report final survival (...) of fulvestrant to anastrozole was associated with increased long-term survival as compared with anastrozole alone, despite substantial crossover to fulvestrant after progression during therapy with anastrozole alone. The results suggest that the benefit was particularly notable in patients without previous exposure to adjuvant endocrine therapy. (Funded by the National Cancer Institute and AstraZeneca; ClinicalTrials.gov number, NCT00075764.).Copyright © 2019 Massachusetts Medical Society.

2019 NEJM

85. Mindfulness-based stress reduction for women diagnosed with breast cancer. (PubMed)

Mindfulness-based stress reduction for women diagnosed with breast cancer. Breast cancer is the most common cancer in women. Diagnosis and treatment may drastically affect quality of life, causing symptoms such as sleep disorders, depression and anxiety. Mindfulness-based stress reduction (MBSR) is a programme that aims to reduce stress by developing mindfulness, meaning a non-judgmental, accepting moment-by-moment awareness. MBSR seems to benefit patients with mood disorders and chronic pain (...) , and it may also benefit women with breast cancer.To assess the effects of mindfulness-based stress reduction (MBSR) in women diagnosed with breast cancer.In April 2018, we conducted a comprehensive electronic search for studies of MBSR in women with breast cancer, in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and two trial registries (World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov). We also handsearched

2019 Cochrane

86. Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries

Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries To investigate whether women with type 2 diabetes (T2D) develop a more advanced stage of breast cancer and whether treatment with insulin (analogs) is associated with specific breast cancer characteristics.For this nested case-control study, women with breast cancer diagnosed in 2002-2014 were selected from the linked Netherlands (...) Cancer Registry-PHARMO Database Network (N = 33,377). T2D was defined as receiving two or more dispensings of noninsulin blood glucose-lowering drugs prior to breast cancer diagnosis. Women with T2D were matched to women without diabetes. Among women with T2D, insulin users and nonusers were compared. Multivariable ordinal logistic regression was used to investigate the association between T2D/insulin and breast cancer characteristics, including TNM classification (tumor size, lymph node status

2019 EvidenceUpdates

87. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health CONSENSUS RECOMMENDATIONS Managementofgenitourinarysyndromeofmenopauseinwomenwith orathighriskforbreastcancer:consensusrecommendationsfromThe North American Menopause Society and The International Society for the Study of Women’s Sexual Health Stephanie S (...) , CCD, NCMP, IF, FACOG, 14 Shari B. Goldfarb, MD, 15 and Sheryl A. Kingsberg, PhD 16 Abstract TheobjectiveofTheNorthAmericanMenopauseSociety(NAMS)andTheInternationalSocietyfortheStudyof Women’s Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendationswillassisthealthcareprovidersinmanagingGSMwithagoalofimprovingthecareandqualityof life

2019 The North American Menopause Society

88. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers The aim of the current study was to conduct a pooled analysis of studies that have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple negative breast cancer (TNBC).Participating studies had evaluated the percentage infiltration of stromally located TILs (sTILs) that were quantified in the same manner in patient diagnostic

2019 EvidenceUpdates

89. Understanding genetic tests for breast and ovarian cancer that runs in the family

Understanding genetic tests for breast and ovarian cancer that runs in the family Understanding genetic tests for breast and ovarian cancer that runs in the family Information and decision aidPublished May 2008 Reprinted January 2014 Current print February 2018 This booklet was developed and printed with the support of: Hereditary Cancer Clinic, Prince of Wales Hospital Macquarie University Centre for Genetics Education, NSW Health, Royal North Shore Hospital Cancer Council NSW Understanding (...) genetic tests for breast and ovarian cancer that runs in the family Information and decision aidWho is this booklet for? This booklet contains information for women who are considering genetic testing for breast and ovarian cancer that runs in their family. This information is not a replacement for discussing genetic testing with your doctor or family cancer services. Choose the sections that are relevant to you, coupled with information from your health professionals, to make an informed decision

2019 European Society of Endocrinology

90. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer Abemaciclib with an aromatase inhibitor Abemaciclib with an aromatase inhibitor for pre for previously untreated, hormone viously untreated, hormone receptor-positiv receptor-positive, HER2-negativ e, HER2-negative, locally e, locally advanced or metastatic breast cancer advanced or metastatic breast cancer T echnology appraisal guidance (...) possible. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 15Contents Contents 1 Recommendations 4 2 Information about abemaciclib 5 3 Committee discussion 6 Current management 6 Clinical evidence 7 Indirect evidence: network meta-analyses 8 Abemaciclib

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

91. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. (PubMed)

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker (...) for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central

2019 NEJM

92. Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment. (PubMed)

Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment. Breast cancer is the most common type of cancer amongst women worldwide, and one distressing complication of breast cancer treatment is breast and upper-limb lymphoedema. There is uncertainty regarding the effectiveness of surgical interventions in both the prevention and management of lymphoedema affecting the arm after breast cancer treatment.1. To assess and compare the efficacy of surgical (...) interventions for the prevention of the development of lymphoedema (LE) in the arm after breast cancer treatment.2. To assess and compare the efficacy of surgical interventions for the treatment of established LE in the arm after breast cancer treatment.We searched the Cochrane Breast Cancer Group's Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the WHO International Clinical Trials Registry

2019 Cochrane

93. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. (PubMed)

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Anthracyclines and taxanes are chemotherapeutic agents widely used in a sequential regimen in the adjuvant and neoadjuvant treatment of early breast cancer to reduce the risk of cancer recurrence. Standard practice is to administer anthracycline-based chemotherapy followed by a taxane. Anthracyclines tend to be administered first as they were established before taxanes for treatment of early (...) breast cancer.To assess whether the sequence in which anthracyclines and taxanes are administered affects outcomes for people with early breast cancer receiving adjuvant or neoadjuvant therapy.We searched Cochrane Breast Cancer's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov on 1 February 2018.Randomised controlled trials comparing administering a taxane prior to an anthracycline

2019 Cochrane

94. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. (PubMed)

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy.To clarify the relative benefits and risks of dose-intense (...) and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded dose-intense versus standard-schedule first-event rate ratios

Full Text available with Trip Pro

2019 Lancet

95. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal (...) breast cancer.This randomised, double-blind, placebo-controlled, phase 3 trial was done in 158 centres in the USA, Canada, and Ireland. Postmenopausal women with stage I-IIIA hormone receptor-positive breast cancer, who were disease-free after about 5 years of treatment with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor, were randomly assigned (1:1) to receive 5 years of letrozole (2·5 mg orally per day) or placebo. Randomisation was stratified by pathological node status

2019 EvidenceUpdates

96. Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer

Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional changes or corrections may appear in these articles when they appear in a future print issue of the Archives. Early Online Release articles are citable by using the Digital Object Identifier (DOI), a unique number (...) given to every article. The DOI will typically appear at the end of the abstract. The DOI for this manuscript is doi: 10.5858/arpa.2018-0378-CP The final published version of this manuscript will replace the Early Online Release version at the above DOI once it is available. © College of American Pathologists 201 9 CAP Laboratory Improvement Programs Quantitative Image AnalysisofHumanEpidermalGrowth Factor Receptor 2 Immunohistochemistry for Breast Cancer Guideline From the College of American

2019 College of American Pathologists

97. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy.Postmenopausal women with ER-positive primary BC and tumors greater

Full Text available with Trip Pro

2019 EvidenceUpdates

98. Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial

Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer.Premenopausal women with stage cT2 to 4b, any N (...) , M0; estrogen receptor and progesterone receptor greater than 50%; human epidermal growth factor receptor 2-negative breast cancer were randomly assigned to triptorelin 3.75 mg administered intramuscularly on day 1 of every cycle or degarelix 240 mg administered subcutaneously (SC) on day 1 of cycle 1 then 80 mg SC on day 1 of cycles 2 through 6, both with letrozole 2.5 mg/day for six 28-day cycles. Surgery was performed 2 to 3 weeks after the last injection. Serum was collected at baseline, after

2019 EvidenceUpdates

99. Effectiveness of a precast adjustable compression system compared to multilayered compression bandages in the treatment of breast cancer-related lymphoedema: a randomized, single-blind clinical trial

Effectiveness of a precast adjustable compression system compared to multilayered compression bandages in the treatment of breast cancer-related lymphoedema: a randomized, single-blind clinical trial To compare the effectiveness of a precast adjustable compression system with that of multilayered compression bandages in the treatment of breast cancer-related lymphoedema.Multicenter, randomized, single-blind parallel-group clinical trial.The rehabilitation services of four general university (...) hospitals.Patients with upper limb breast cancer-related lymphoedema.All the patients received manual lymphatic drainage, followed by a precast adjustable compression system or multilayered compression bandages, according to the group allocation. The treatment included 10 consecutive sessions over a two-week period from Monday to Friday, followed by some sessions on three alternate days per week, until the patient received a tailored compression garment.The patients were evaluated just before the treatment

2019 EvidenceUpdates

100. The impact of intravenous dexamethasone on the efficacy and duration of analgesia of paravertebral block in breast cancer surgery: a randomized controlled trial

The impact of intravenous dexamethasone on the efficacy and duration of analgesia of paravertebral block in breast cancer surgery: a randomized controlled trial The study aimed at the evaluation of the impact of intravenous (IV) dexamethasone on efficacy and duration of analgesia of paravertebral block (PVB) in patients undergoing modified radical mastectomy (MRM).This randomized, double-blind controlled trial included 50 patients with breast cancer scheduled for unilateral MRM. Ultrasound (...) ). The VAS scores were significantly lower in Group DB compared to Group B up to 12 hours postoperatively. Morphine consumption was lower in Group DB compared to Group B. PONV Impact Scale score was significantly higher in Group B.Systemic dexamethasone increased the efficacy and duration of the single-shot multilevel PVB in breast cancer surgery.ISRCTN registry, study ID: ISRCTN15920148.

2019 EvidenceUpdates